Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (DE:F6T)
FRANKFURT:F6T
Fate Therapeutics (F6T) Ownership Overview
18.11% Insiders
15.88%
Mutual Funds
39.29% Other Institutional Investors
10.33% ETFs
16.39% Public Companies and
Individual Investors
The ownership structure of Fate Therapeutics (DE:F6T) stock is a mix of institutional, retail, and individual investors. Approximately 65.50% of the company’s stock is owned by Institutional Investors, 18.11% is owned by Insiders, and 16.39% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Jan 13, 2025 | Jerome Charles Bressi Chief Regulatory And Quality Officer | xxxxxxxxxxxxx | $9269 |
| Jan 13, 2025 | Cindy Tahl Chief Legal & Compliance Officer And Secretary | xxxxxxxxxxxxx | $8764 |
| Jan 13, 2025 | Bahram Valamehr President & Ceo,director | xxxxxxxxxxxxx | $13406 |
| Dec 26, 2024 | Redmile Group, Llc Director, >10% Owner | xxxxxxxxxxxxx | $668580 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $36864 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $2347595 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $5376363 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 12,884,277 | Insider | 11.24% | 11,892,188 | |
| 4,945,146 | Insider | 5.00% | 4,564,370 | |
| 5,255,435 | Institution | 4.59% | 4,850,767 | |
| 4,747,702 | Institution | 4.14% | 4,382,129 | |
| 4,453,203 | Institution | 3.89% | 4,110,306 | |
| 3,555,871 | Institution | 3.10% | 3,282,069 | |
| 3,258,402 | Institution | 2.84% | 3,007,505 | |
| 2,904,835 | Institution | 2.53% | 2,681,163 | |
| 1,422,785 | Institution | 1.24% | 1,313,231 | |
| 1,361,334 | Institution | 1.19% | 1,256,511 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,453,203 | Institution | 3.89% | 4,110,306 | |
| 2,904,835 | Institution | 2.53% | 2,681,163 | |
| 1,361,334 | Institution | 1.19% | 1,256,511 | |
| 1,268,133 | Institution | 1.11% | 1,170,487 | |
| 1,138,815 | Institution | 0.99% | 1,051,126 | |
| 1,034,885 | Institution | 0.90% | 955,199 | |
| 904,537 | Institution | 0.79% | 834,888 | |
| 545,614 | Institution | 0.48% | 503,602 | |
| 510,751 | Institution | 0.45% | 471,423 | |
| 506,501 | Institution | 0.44% | 467,500 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Fate Therapeutics (DE:F6T)?
According to the latest TipRanks data, approximately 39.29% of the company's stock is held by institutional investors, 18.11% is held by insiders, and 16.39% is held by retail investors.
What percentage of Fate Therapeutics (DE:F6T) stock is held by institutional investors?
According to the latest TipRanks data, approximately 39.29% of Fate Therapeutics (DE:F6T) stock is held by institutional investors.
What percentage of Fate Therapeutics (DE:F6T) stock is held by retail investors?
According to the latest TipRanks data, approximately 16.39% of Fate Therapeutics (DE:F6T) stock is held by retail investors.
Who owns the most shares of Fate Therapeutics (DE:F6T)?
Redmile Group, Llc owns the most shares of Fate Therapeutics (DE:F6T).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.